Significant opportunities exist in the global pain market for novel mechanisms and modalities
Pain is a multifaceted, highly heterogeneous disorder that is treated using analgesics. There is a lack of diversity within the…
Central Nervous System
-
-
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining…
-
Biogen’s Tysabri to be used on England’s NHS for highly active MS
The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly active…
-
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting induced by…
-
Nxera seeks schizophrenia programme buyer after Boehringer snub
Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead…
-
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they…
-
High-dose Spinraza inches closer to EU approval despite FDA setback
A high-dose version of Biogen’s Spinraza (nusinersen) could soon be available in Europe, after a panel recommended the formulation’s approval.…
-
Modulight secures $12m to shine precise light on neurological diseases
Modulight Biotherapeutics has raised $12.2m in seed financing to advance its optogenetic technology being developed for neurological disorders. The seed…
